HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adverse events associated with poor neurological outcome during targeted temperature management and advanced critical care after out-of-hospital cardiac arrest.

AbstractINTRODUCTION:
The aim of this study was to investigate the association of adverse events (AEs) during targeted temperature management (TTM) and other AEs and concomitant treatments during the advanced critical care period with poor neurological outcome at hospital discharge in adult out-of-hospital cardiac arrest (OHCA) patients.
METHODS:
This was a retrospective study using Korean Hypothermia Network registry data of adult OHCA patients treated with TTM in 24 teaching hospitals throughout South Korea from 2007 to 2012. Demographic characteristics, resuscitation and post-resuscitation variables, AEs, and concomitant treatments during TTM and the advanced critical care were collected. The primary outcome was poor neurological outcome, defined as a cerebral performance category (CPC) score of 3-5 at hospital discharge. The AEs and concomitant treatments were individually entered into the best multivariable predictive model of poor neurological outcome to evaluate the associations between each variable and outcome.
RESULTS:
A total of 930 patients, including 704 for whom a complete dataset of AEs and covariates was available for multivariable modeling, were included in the analysis; 476 of these patients exhibited poor neurological outcome [CPC 3 = 50 (7.1%), CPC 4 = 214 (30.4%), and CPC 5 = 212 (30.1%)]. Common AEs included hyperglycemia (45.6%), hypokalemia (31.3%), arrhythmia (21.3%) and hypotension (29%) during cooling, and hypotension (21.6%) during rewarming. Bleeding (5%) during TTM was a rare AE. Common AEs during the advanced critical care included pneumonia (39.6%), myoclonus (21.9%), seizures (21.7%) and hypoglycemia within 72 hours (23%). After adjusting for independent predictors of outcome, cooling- and rewarming-related AEs were not significantly associated with poor neurological outcome. However, sepsis, myoclonus, seizure, hypoglycemia within 72 hours and anticonvulsant use during the advanced critical care were associated with poor neurological outcome [adjusted odds ratios (95% confidence intervals) of 3.12 (1.40-6.97), 3.72 (1.93-7.16), 4.02 (2.04-7.91), 2.03 (1.09-3.78), and 1.69 (1.03-2.77), respectively]. Alternatively, neuromuscular blocker use was inversely associated with poor neurological outcome (0.48 [0.28-0.84]).
CONCLUSIONS:
Cooling- and rewarming-related AEs were not associated with poor neurological outcome at hospital discharge. Sepsis, myoclonus, seizure, hypoglycemia within 72 hours and anticonvulsant use during the advanced critical care period were associated with poor neurological outcome at hospital discharge in our study.
AuthorsYoung-Min Kim, Chun Song Youn, Soo Hyun Kim, Byung Kook Lee, In Soo Cho, Gyu Chong Cho, Kyung Woon Jeung, Sang Hoon Oh, Seung Pill Choi, Jong Hwan Shin, Kyoung-Chul Cha, Joo Suk Oh, Hyeon Woo Yim, Kyu Nam Park, Korean Hypothermia Network Investigators
JournalCritical care (London, England) (Crit Care) Vol. 19 Pg. 283 (Jul 22 2015) ISSN: 1466-609X [Electronic] England
PMID26202789 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Anticonvulsants
  • Neuromuscular Blocking Agents
Topics
  • Adult
  • Aged
  • Anticonvulsants (therapeutic use)
  • Female
  • Hospitals, Teaching
  • Humans
  • Hypoglycemia (epidemiology)
  • Hypothermia, Induced
  • Male
  • Middle Aged
  • Myoclonus (epidemiology)
  • Neuromuscular Blocking Agents (therapeutic use)
  • Out-of-Hospital Cardiac Arrest (epidemiology, therapy)
  • Patient Discharge
  • Patient Outcome Assessment
  • Registries
  • Republic of Korea (epidemiology)
  • Retrospective Studies
  • Rewarming
  • Seizures (drug therapy, epidemiology)
  • Sepsis (epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: